Aquino-Galvez, A., Gonzalez-Avila, G., Delgado-Tello, J., Castillejos-Lopez, M., Mendoza-Milla, C., Zuniga, J., Checa, M., Maldonado-Martinez, H. A., Trinidad-Lopez, A., Cisneros, J., Torres-Espindola, L. M., Hernandez-Jimenez, C., Sommer, B., Cabello-Gutierrez, C., & Gutierrez-Gonzalez, L. H. (2016). Effects of 2-methoxyestradiol on apoptosis and HIF-1α and HIF-2α expression in lung cancer cells under normoxia and hypoxia. Oncology Reports, 35(1), 577–583. https://doi.org/10.3892/or.2015.4399

 

Arnaiz, E., Miar, A., Bridges, E., Prasad, N., Hatch, S. B., Ebner, D., Lawrie, C. H., & Harris, A. L. (2021). Differential effects of HIF-2α antagonist and HIF-2α silencing in renal cancer and sensitivity to repurposed drugs. BMC Cancer, 21(1). https://doi.org/10.1186/s12885-021-08616-8

 

Bailey, C. M., Liu, Y., Liu, M., Du, X., Devenport, M., Zheng, P., Liu, Y., & Wang, Y. (2022). Targeting HIF-1α abrogates PD-L1-mediated immune evasion in tumor microenvironment but promotes tolerance in normal tissues. Journal of Clinical Investigation, 132(9). https://doi.org/10.1172/jci150846

 

Ball, A. T., Mohammed, S., Doigneaux, C., Gardner, R. M., Easton, J. W., Turner, S., Essex, J. W., Pairaudeau, G., & Tavassoli, A. (2024). Identification and development of cyclic peptide inhibitors of HIF-1α and 2α that disrupt hypoxia-response signaling in cancer cells. Journal of the American Chemical Society, 146(13), 8877–8886. https://doi.org/10.1021/jacs.3c10508

 

Bartholomaus, I., Kawakami, N., Odoardi, F., Schlager, C., Miljkovic, D., Ellwart, J. W., Klinkert, W. E., Flugel-Koch, C., Issekutz, T. B., Wekerle, H., & Flugel, A. (2009). Effector T cell interactions with meningeal vascular structures in nascent autoimmune CNS lesions. Nature, 462(7269), 94–98. https://doi.org/10.1038/nature08478

 

Becker, C. M., Rohwer, N., Funakoshi, T., Cramer, T., Bernhardt, W., Birsner, A., Folkman, J., & D’Amato, R. J. (2008). 2-methoxyestradiol inhibits HIF-1α and suppresses growth of lesions in a mouse model of endometriosis. American Journal of Pathology, 172(2), 534–544. https://doi.org/10.2353/ajpath.2008.061244

 

Bertout, J. A., Majmundar, A. J., Gordan, J. D., Lam, J. C., Ditsworth, D., Keith, B., Brown, E. J., Nathanson, K. L., & Simon, M. C. (2009). HIF-2α inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proceedings of the National Academy of Sciences of the United States of America, 106(34), 14391–14396. https://doi.org/10.1073/pnas.0907357106

 

Beziaud, L., Mansi, L., Ravel, P., Marie-Joseph, E. L., Laheurte, C., Rangan, L., Bonnefoy, F., Pallandre, J. R., Boullerot, L., Gamonet, C., Vrecko, S., Queiroz, L., Maurina, T., Mouillet, G., Hon, T. N., Curtit, E., Royer, B., Gaugler, B., Bayry, J., … Adotevi, O. (2016). Rapalogs efficacy relies on the modulation of antitumor T-cell immunity. Cancer Research, 76(14), 4100–4112. https://doi.org/10.1158/0008-5472.Can-15-2452

 

Birle, D. C., & Hedley, D. W. (2007). Suppression of the HIF-1α response in cervical carcinoma xenografts by proteasome inhibitors. Cancer Research, 67(4), 1735–1743. https://doi.org/10.1158/0008-5472.Can-06-2722

 

Blengio, F., Raggi, F., Pierobon, D., Cappello, P., Eva, A., Giovarelli, M., Varesio, L., & Bosco, M. C. (2013). The hypoxic environment reprograms the cytokine/chemokine expression profile of human mature dendritic cells. Immunobiology, 218(1), 76–89. https://doi.org/10.1016/j.imbio.2012.02.002

 

Bristow, R. G., & Hill, R. P. (2008). Hypoxia and metabolism: Hypoxia, DNA repair and genetic instability. Nature Reviews Cancer, 8(3), 180–192. https://doi.org/10.1038/nrc2344

 

Brugarolas, J. (2007). Renal-cell carcinoma--molecular pathways and therapies. New England Journal of Medicine, 356(2), 185–187. https://doi.org/10.1056/NEJMe068263

 

Bruick, R. K., & McKnight, S. L. (2001). A conserved family of prolyl-4-hydroxylases that modify HIF. Science, 294(5545), 1337–1340. https://doi.org/10.1126/science.1066373

 

Burslem, G. M., Kyle, H. F., Breeze, A. L., Edwards, T. A., Nelson, A., Warriner, S. L., & Wilson, A. J. (2014). Small-molecule proteomimetic inhibitors of the HIF-1α-p300 protein-protein interaction. ChemBioChem, 15(8), 1083–1087. https://doi.org/10.1002/cbic.201400009

 

Cairns, R. A., Papandreou, I., Sutphin, P. D., & Denko, N. C. (2007). Metabolic targeting of hypoxia and HIF-1α in solid tumors can enhance cytotoxic chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 104(22), 9445–9450. https://doi.org/10.1073/pnas.0611662104

 

Carmeliet, P., & Jain, R. K. (2000). Angiogenesis in cancer and other diseases. Nature, 407(6801), 249–257. https://doi.org/10.1038/35025220

 

Chang, C. H., Qiu, J., O’Sullivan, D., Buck, M. D., Noguchi, T., Curtis, J. D., Chen, Q., Gindin, M., Gubin, M. M., van der Windt, G. J., Tonc, E., Schreiber, R. D., Pearce, E. J., & Pearce, E. L. (2015). Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell, 162(6), 1229–1241. https://doi.org/10.1016/j.cell.2015.08.016

 

Chang, Y. L., Yang, C. Y., Lin, M. W., Wu, C. T., & Yang, P. C. (2016). High co-expression of PD-L1 and HIF-1α correlates with tumour necrosis in pulmonary pleomorphic carcinoma. European Journal of Cancer, 60, 125–135. https://doi.org/10.1016/j.ejca.2016.03.012

 

Chapman-Smith, A., Lutwyche, J. K., & Whitelaw, M. L. (2004). Contribution of the Per/Arnt/Sim (PAS) domains to DNA binding by the basic helix-loop-helix PAS transcriptional regulators. Journal of Biological Chemistry, 279(7), 5353–5362. https://doi.org/10.1074/jbc.M310041200

 

Chen, W., Lin, C., Gao, Z., Huang, Y., Wang, X., Zhang, Q., Zhang, Y., Tan, M., & Hou, Z. (2025). A tumor microenvironment-responsive nanocomposite for enhanced copper retention and hypoxia reversal to promote cuproptosis in tumor treatment. Acta Biomaterialia, 202, 463–475. https://doi.org/10.1016/j.actbio.2025.07.013

 

Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023). Hypoxic microenvironment in cancer: Molecular mechanisms and therapeutic interventions. Signal Transduction and Targeted Therapy, 8(1). https://doi.org/10.1038/s41392-023-01332-8

 

Cho, H., Du, X., Rizzi, J. P., Liberzon, E., Chakraborty, A. A., Gao, W., Carvo, I., Signoretti, S., Bruick, R. K., Josey, J. A., Wallace, E. M., & Kaelin, W. G. (2016). On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models. Nature, 539(7627), 107–111. https://doi.org/10.1038/nature19795

 

Choueiri, T. K., Bauer, T. M., Papadopoulos, K. P., Plimack, E. R., Merchan, J. R., McDermott, D. F., Michaelson, M. D., Appleman, L. J., Thamake, S., Perini, R. F., Zojwalla, N. J., & Jonasch, E. (2021). Inhibition of HIF-2α in renal cell carcinoma with belzutifan: A phase 1 trial and biomarker analysis. Nature Medicine, 27(5), 802–805. https://doi.org/10.1038/s41591-021-01324-7

 

Chua, Y. S., Chua, Y. L., & Hagen, T. (2010). Structure activity analysis of 2-methoxyestradiol analogues reveals targeting of microtubules as the major mechanism of antiproliferative and proapoptotic activity. Molecular Cancer Therapeutics, 9(1), 224–235. https://doi.org/10.1158/1535-7163.Mct-09-1003

 

Clambey, E. T., McNamee, E. N., Westrich, J. A., Glover, L. E., Campbell, E. L., Jedlicka, P., de Zoeten, E. F., Cambier, J. C., Stenmark, K. R., Colgan, S. P., & Eltzschig, H. K. (2012). HIF- 1α-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proceedings of the National Academy of Sciences of the United States of America, 109(41), E2784–E2793. https://doi.org/10.1073/pnas.1202366109

 

Cockman, M. E., Masson, N., Mole, D. R., Jaakkola, P., Chang, G. W., Clifford, S. C., Maher, E. R., Pugh, C. W., Ratcliffe, P. J., & Maxwell, P. H. (2000). HIF-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. Journal of Biological Chemistry, 275(33), 25733–25741. https://doi.org/10.1074/jbc.M002740200

 

Codo, A. C., Davanzo, G. G., Monteiro, L. B., de Souza, G. F., Muraro, S. P., Virgilio-da-Silva, J. V., Prodonoff, J. S., Carregari, V. C., de Biagi Junior, C. A. O., Crunfli, F., Jimenez Restrepo, J. L., Vendramini, P. H., Reis-de-Oliveira, G., Bispo Dos Santos, K., Toledo-Teixeira, D. A., Parise, P. L., Martini, M. C., Marques, R. E., Carmo, H. R., … Moraes-Vieira, P. M. (2020). Elevated glucose levels favor SARSCoV-2 infection and monocyte response through a HIF-1α/glycolysis-dependent axis. Cell Metabolism, 32(3), 437–446.e5. https://doi.org/10.1016/j.cmet.2020.07.007

 

Corzo, C. A., Condamine, T., Lu, L., Cotter, M. J., Youn, J. I., Cheng, P., Cho, H. I., Celis, E., Quiceno, D. G., Padhya, T., McCaffrey, T. V., McCaffrey, J. C., & Gabrilovich, D. I. (2010). HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. Journal of Experimental Medicine, 207(11), 2439–2453. https://doi.org/10.1084/jem.20100587

 

Courtney, K. D., Ma, Y., Diaz de Leon, A., Christie, A., Xie, Z., Woolford, L., Singla, N., Joyce, A., Hill, H., Madhuranthakam, A. J., Yuan, Q., Xi, Y., Zhang, Y., Chang, J., Fatunde, O., Arriaga, Y., Frankel, A. E., Kalva, S., Zhang, S., … Brugarolas, J. (2020). HIF-2α complex dissociation, target inhibition, and acquired resistance with PT2385, a first-in-class HIF-2α inhibitor, in patients with clear cell renal cell carcinoma. Clinical Cancer Research, 26(4), 793–803. https://doi.org/10.1158/1078-0432.Ccr-19-1459

 

Cowman, S. J., & Koh, M. Y. (2022). Revisiting the HIF switch in the tumor and its immune microenvironment. Trends in Cancer, 8(1), 28–42. https://doi.org/10.1016/j.trecan.2021.10.004

 

Cramer, T., Yamanishi, Y., Clausen, B. E., Forster, I., Pawlinski, R., Mackman, N., Haase, V. H., Jaenisch, R., Corr, M., Nizet, V., Firestein, G. S., Gerber, H. P., Ferrara, N., & Johnson, R. S. (2003). HIF-1α is essential for myeloid cell-mediated inflammation. Cell, 112(5), 645–657. https://doi.org/10.1016/s0092-8674(03)00154-5

 

Cui, H., Qin, Q., Yang, M., Zhang, H., Liu, Z., Yang, Y., Chen, X., Zhu, H., Wang, D., Meng, C., Song, H., Ma, J., Huang, G., Cai, J., Sun, X., & Wang, Z. (2015). Bortezomib enhances the radiosensitivity of hypoxic cervical cancer cells by inhibiting HIF-1α expression. International Journal of Clinical and Experimental Pathology, 8(8), 9032–9041.

 

Dang, B., Gao, Q., Zhang, L., Zhang, J., Cai, H., Zhu, Y., Zhong, Q., Liu, J., Niu, Y., Mao, K., Xiao, N., Liu, W. H., Lin, S. H., Huang, J., Huang, S. C., Ho, P. C., & Cheng, S. C. (2023). The glycolysis/HIF-1α axis defines the inflammatory role of IL-4-primed macrophages. Cell Reports, 42(5), 112471. https://doi.org/10.1016/j.celrep.2023.112471

 

Ding, X., Huang, R., Zhong, Y., Cui, N., Wang, Y., Weng, J., Chen, L., & Zang, M. (2020). CTHRC1 promotes gastric cancer metastasis via HIF-1α/CXCR4 signaling pathway. Biomedicine & Pharmacotherapy, 123, 109742. https://doi.org/10.1016/j.biopha.2019.109742

 

Doedens, A. L., Stockmann, C., Rubinstein, M. P., Liao, D., Zhang, N., DeNardo, D. G., Coussens, L. M., Karin, M., Goldrath, A. W., & Johnson, R. S. (2010). Macrophage expression of HIF-1α suppresses T-cell function and promotes tumor progression. Cancer Research, 70(19), 7465–7475. https://doi.org/10.1158/0008-5472.Can-10-1439

 

Escuin, D., Kline, E. R., & Giannakakou, P. (2005). Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit HIF-1α accumulation and activity by disrupting microtubule function. Cancer Research, 65(19), 9021–9028. https://doi.org/10.1158/0008-5472.Can-04-4095

 

Espinoza, F. I., Tankov, S., Chliate, S., Pereira Couto, J., Marinari, E., Vermeil, T., Lecoultre, M., El Harane, N., Dutoit, V., Migliorini, D., & Walker, P. R. (2025). Targeting HIF-2α in glioblastoma reshapes the immune infiltrate and enhances response to immune checkpoint blockade. Cellular and Molecular Life Sciences, 82(1). https://doi.org/10.1007/s00018-025-05642-8

 

Estephan, H., Tailor, A., Parker, R., Kreamer, M., Papandreou, I., Campo, L., Easton, A., Moon, E. J., Denko, N. C., Ternette, N., Hammond, E. M., & Giaccia, A. J. (2025). Hypoxia promotes tumor immune evasion by suppressing MHC-I expression and antigen presentation. EMBO Journal, 44(3), 903–922. https://doi.org/10.1038/s44318-024-00319-7

 

Feng, Z., Zou, X., Chen, Y., Wang, H., Duan, Y., & Bruick, R. K. (2018). Modulation of HIF-2α PAS-B domain contributes to physiological responses. Proceedings of the National Academy of Sciences of the United States of America, 115(52), 13240–13245. https://doi.org/10.1073/pnas.1810897115

 

Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried, E., Schwarz, S., Rothe, G., Hoves, S., Renner, K., Timischl, B., Mackensen, A., Kunz-Schughart, L., Andreesen, R., Krause, S. W., & Kreutz, M. (2007). Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood, 109(9), 3812–3819. https://doi.org/10.1182/blood-2006-07-035972

 

Freedman, S. J., Sun, Z. Y., Poy, F., Kung, A. L., Livingston, D. M., Wagner, G., & Eck, M. J. (2002). Structural basis for recruitment of CBP/p300 by HIF-1α. Proceedings of the National Academy of Sciences of the United States of America, 99(8), 5367–5372.  https://doi.org/10.1073/pnas.082117899

 

Gameiro, P. A., Yang, J., Metelo, A. M., Perez-Carro, R., Baker, R., Wang, Z., Arreola, A., Rathmell, W. K., Olumi, A., Lopez-Larrubia, P., Stephanopoulos, G., & Iliopoulos, O. (2013). In vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metabolism, 17(3), 372–385. https://doi.org/10.1016/j.cmet.2013.02.002

 

Garcia Garcia, C. J., Huang, Y., Fuentes, N. R., Turner, M. C., Monberg, M. E., Lin, D., Nguyen, N. D., Fujimoto, T. N., Zhao, J., Lee, J. J., Bernard, V., Yu, M., Delahoussaye, A. M., Jimenez Sacarello, I., Caggiano, E. G., Phan, J. L., Deorukhkar, A., Molkentine, J. M., Saur, D., … Taniguchi, C. M. (2022). Stromal HIF-2α regulates immune suppression in the pancreatic cancer microenvironment. Gastroenterology, 162(7), 2018–2031. https://doi.org/10.1053/j.gastro.2022.02.024

 

Guo, X., Xue, H., Shao, Q., Wang, J., Guo, X., Chen, X., Zhang, J., Xu, S., Li, T., Zhang, P., Gao, X., Qiu, W., Liu, Q., & Li, G. (2016). Hypoxia promotes glioma-associated macrophage infiltration via periostin and subsequent M2 polarization by upregulating TGF-beta and M-CSFR. Oncotarget, 7(49), 80521–80542. https://doi.org/10.18632/oncotarget.11825

 

Hajizadeh, F., Moghadaszadeh Ardebili, S., Baghi Moornani, M., Masjedi, A., Atyabi, F., Kiani, M., Namdar, A., Karpisheh, V., Izadi, S., Baradaran, B., Azizi, G., Ghalamfarsa, G., Sabz, G., Yousefi, M., & Jadidi-Niaragh, F. (2020). Silencing of HIF-1α/CD73 axis by siRNA-loaded TATchitosan-spion nanoparticles robustly blocks cancer cell progression. European Journal of Pharmacology, 882, 173235. https://doi.org/10.1016/j.ejphar.2020.173235

 

Hallis, S. P., Kim, S. K., Lee, J. H., & Kwak, M. K. (2023). Association of NRF2 with HIF-2α-induced cancer stem cell phenotypes in chronic hypoxic condition. Redox Biology, 60, 102632. https://doi.org/10.1016/j.redox.2023.102632

 

Hamzah, J., Jugold, M., Kiessling, F., Rigby, P., Manzur, M., Marti, H. H., Rabie, T., Kaden, S., Grone, H. J., Hammerling, G. J., Arnold, B., & Ganss, R. (2008). Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature, 453(7193), 410–414. https://doi.org/10.1038/nature06868

 

Hatfield, S. M., & Sitkovsky, M. (2016). A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer. Current Opinion in Pharmacology, 29, 90–96. https://doi.org/10.1016/j.coph.2016.06.009

 

He, H., Liao, Q., Zhao, C., Zhu, C., Feng, M., Liu, Z., Jiang, L., Zhang, L., Ding, X., Yuan, M., Zhang, X., & Xu, J. (2021). Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy. Journal for ImmunoTherapy of Cancer, 9(10), e002755. https://doi.org/10.1136/jitc-2021-002755

 

Hoefflin, R., Harlander, S., Schafer, S., Metzger, P., Kuo, F., Schonenberger, D., Adlesic, M., Peighambari, A., Seidel, P., Chen, C. Y., Consenza-Contreras, M., Jud, A., Lahrmann, B., Grabe, N., Heide, D., Uhl, F. M., Chan, T. A., Duyster, J., Zeiser, R., … Frew, I. J. (2020). HIF-1α and HIF-2α differently regulate tumour development and inflammation of clear cell renal cell carcinoma in mice. Nature Communications, 11(1). https://doi.org/10.1038/s41467-020-17873-3

 

Holmquist-Mengelbier, L., Fredlund, E., Lofstedt, T., Noguera, R., Navarro, S., Nilsson, H., Pietras, A., Vallon-Christersson, J., Borg, A., Gradin, K., Poellinger, L., & Pahlman, S. (2006). Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotype. Cancer Cell, 10(5), 413–423. https://doi.org/10.1016/j.ccr.2006.08.026

 

Hsiao, H. W., Hsu, T. S., Liu, W. H., Hsieh, W. C., Chou, T. F., Wu, Y. J., Jiang, S. T., & Lai, M. Z. (2015). Deltex1 antagonizes HIF-1α and sustains the stability of regulatory T cells in vivo. Nature Communications, 6(1). https://doi.org/10.1038/ncomms7353

 

Hsu, T. S., Lin, Y. L., Wang, Y. A., Mo, S. T., Chi, P. Y., Lai, A. C., Pan, H. Y., Chang, Y. J., & Lai, M. Z. (2020). HIF-2α is indispensable for regulatory T cell function. Nature Communications, 11(1), 5005. https://doi.org/10.1038/s41467-020-18731-y

 

Hu, C. J., Wang, L. Y., Chodosh, L. A., Keith, B., & Simon, M. C. (2003). Differential roles of HIF-1α and HIF-2α in hypoxic gene regulation. Molecular and Cellular Biology, 23(24), 9361–9374. https://doi.org/10.1128/mcb.23.24.9361-9374.2003

 

Huang, D., Li, T., Li, X., Zhang, L., Sun, L., He, X., Zhong, X., Jia, D., Song, L., Semenza, G. L., Gao, P., & Zhang, H. (2014). HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression. Cell Reports, 8(6), 1930–1942. https://doi.org/10.1016/j.celrep.2014.08.028

 

Imamura, T., Kikuchi, H., Herraiz, M. T., Park, D. Y., Mizukami, Y., Mino-Kenduson, M., Lynch, M. P., Rueda, B. R., Benita, Y., Xavier, R. J., & Chung, D. C. (2009). HIF-1α and HIF-2α have divergent roles in colon cancer. International Journal of Cancer, 124(4), 763–771. https://doi.org/10.1002/ijc.24032

 

Imtiyaz, H. Z., Williams, E. P., Hickey, M. M., Patel, S. A., Durham, A. C., Yuan, L. J., Hammond, R., Gimotty, P. A., Keith, B., & Simon, M. C. (2010). HIF-2α regulates macrophage function in mouse models of acute and tumor inflammation. Journal of Clinical Investigation, 120(8), 2699–2714. https://doi.org/10.1172/jci39506

 

Isaacs, J. S., Jung, Y. J., Mimnaugh, E. G., Martinez, A., Cuttitta, F., & Neckers, L. M. (2002). Hsp90 regulates a von Hippel Lindau-independent HIF-1α-degradative pathway. Journal of Biological Chemistry, 277(33), 29936–29944. https://doi.org/10.1074/jbc.M204733200

 

Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin, W. G., Jr. (2001). HIFα targeted for VHL-mediated destruction by proline hydroxylation: Implications for O2 sensing. Science, 292(5516), 464–468. https://doi.org/10.1126/science.1059817

 

Jaakkola, P., Mole, D. R., Tian, Y. M., Wilson, M. I., Gielbert, J., Gaskell, S. J., von Kriegsheim, A., Hebestreit, H. F., Mukherji, M., Schofield, C. J., Maxwell, P. H., Pugh, C. W., & Ratcliffe, P. J. (2001). Targeting of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science, 292(5516), 468–472. https://doi.org/10.1126/science.1059796

 

Jain, R. K. (2005). Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy. Science, 307(5706), 58–62. https://doi.org/10.1126/science.1104819

 

Jansen, C. S., Prokhnevska, N., Master, V. A., Sanda, M. G., Carlisle, J. W., Bilen, M. A., Cardenas, M., Wilkinson, S., Lake, R., Sowalsky, A. G., Valanparambil, R. M., Hudson, W. H., McGuire, D., Melnick, K., Khan, A. I., Kim, K., Chang, Y. M., Kim, A., Filson, C. P., … Kissick, H. (2019). An intratumoral niche maintains and differentiates stem-like CD8 T cells. Nature, 576(7787), 465–470. https://doi.org/10.1038/s41586-019-1836-5

 

Jeong, W., Rapisarda, A., Park, S. R., Kinders, R. J., Chen, A., Melillo, G., Turkbey, B., Steinberg, S. M., Choyke, P., Doroshow, J. H., & Kummar, S. (2014). Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of HIF-1α, in patients with refractory solid tumors. Cancer Chemotherapy and Pharmacology, 73(2), 343–348. https://doi.org/10.1007/s00280-013-2362-z

 

Jiang, B. H., Rue, E., Wang, G. L., Roe, R., & Semenza, G. L. (1996). Dimerization, DNA binding, and transactivation properties of HIF-1. Journal of Biological Chemistry, 271(30), 17771–17778. https://doi.org/10.1074/jbc.271.30.17771

 

Jiang, P., Gu, S., Pan, D., Fu, J., Sahu, A., Hu, X., Li, Z., Traugh, N., Bu, X., Li, B., Liu, J., Freeman, G. J., Brown, M. A., Wucherpfennig, K. W., & Liu, X. S. (2018). Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nature Medicine, 24(10), 1550–1558. https://doi.org/10.1038/s41591-018-0136-1

 

Jiang, W., Huang, Y., An, Y., & Kim, B. Y. (2015). Remodeling tumor vasculature to enhance delivery of intermediate-sized nanoparticles. ACS Nano, 9(9), 8689–8696. https://doi.org/10.1021/acsnano.5b02028

 

Jonasch, E., Donskov, F., Iliopoulos, O., Rathmell, W. K., Narayan, V. K., Maughan, B. L., Oudard, S., Else, T., Maranchie, J. K., Welsh, S. J., Thamake, S., Park, E. K., Perini, R. F., Linehan, W. M., & Srinivasan, R. (2021). Belzutifan for renal cell carcinoma in von Hippel-Lindau disease. New England Journal of Medicine, 385(22), 2036–2046. https://doi.org/10.1056/nejmoa2103425

 

Kai, A. K., Chan, L. K., Lo, R. C., Lee, J. M., Wong, C. C., Wong, J. C., & Ng, I. O. (2016). Down-regulation of TIMP2 by HIF-1α/miR-210/HIF-3α regulatory feedback circuit enhances cancer metastasis in hepatocellular carcinoma. Hepatology, 64(2), 473–487. https://doi.org/10.1002/hep.28577

 

Kaidi, A., Williams, A. C., & Paraskeva, C. (2007). Interaction between beta-catenin and HIF-1α promotes cellular adaptation to hypoxia. Nature Cell Biology, 9(2), 210–217. https://doi.org/10.1038/ncb1534

 

Kaluz, S., Kaluzova, M., & Stanbridge, E. J. (2008). Regulation of gene expression by hypoxia: Integration of the HIF-transduced hypoxic signal at the hypoxia-responsive element. Clinica Chimica Acta, 395(1-2), 6–13. https://doi.org/10.1016/j.cca.2008.05.002

 

Kang, S., Onishi, S., Ling, Z., Inoue, H., Zhang, Y., Chang, H., Zhao, H., Wang, T., Okuzaki, D., Matsuura, H., Takamatsu, H., Oda, J., & Kishimoto, T. (2024). Gp130-HIF-1α axis-induced vascular damage is prevented by the short-term inhibition of IL-6 receptor signaling. Proceedings of the National Academy of Sciences of the United States of America, 121(2). https://doi.org/10.1073/pnas.2315898120

 

Kim, J. W., Evans, C., Weidemann, A., Takeda, N., Lee, Y. S., Stockmann, C., Branco-Price, C., Brandberg, F., Leone, G., Ostrowski, M. C., & Johnson, R. S. (2012). Loss of fibroblast HIF-1α accelerates tumorigenesis. Cancer Research, 72(13), 3187–3195. https://doi.org/10.1158/0008-5472.Can-12-0534

 

Kim, J. W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006). HIF-1α-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metabolism, 3(3), 177–185. https://doi.org/10.1016/j.cmet.2006.02.002

 

Kim, T. H., Hur, E. G., Kang, S. J., Kim, J. A., Thapa, D., Lee, Y. M., Ku, S. K., Jung, Y., & Kwak, M. K. (2011). NRF2 blockade suppresses colon tumor angiogenesis by inhibiting hypoxia-induced activation of HIF-1α. Cancer Research, 71(6), 2260–2275. https://doi.org/10.1158/0008-5472.Can-10-3007

 

Koh, M. Y., Spivak-Kroizman, T., Venturini, S., Welsh, S., Williams, R. R., Kirkpatrick, D. L., & Powis, G. (2008). Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of HIF-1α. Molecular Cancer Therapeutics, 7(1), 90–100. https://doi.org/10.1158/1535-7163.Mct-07-0463

 

Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., Fisher, R. J., Shoemaker, R. H., & Melillo, G. (2005). Echinomycin, a small-molecule inhibitor of HIF-1α DNA-binding activity. Cancer Research, 65(19), 9047–9055. https://doi.org/10.1158/0008-5472.Can-05-1235

 

Kosti, P., Opzoomer, J. W., Larios-Martinez, K. I., Henley-Smith, R., Scudamore, C. L., Okesola, M., Taher, M. Y. M., Davies, D. M., Muliaditan, T., Larcombe-Young, D., Woodman, N., Gillett, C. E., Thavaraj, S., Maher, J., & Arnold, J. N. (2021). Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. Cell Reports Medicine, 2(4), 100227. https://doi.org/10.1016/j.xcrm.2021.100227

 

Kumar, V., & Gabrilovich, D. I. (2014). HIFs in regulation of immune responses in tumour microenvironment. Immunology, 143(4), 512–519. https://doi.org/10.1111/imm.12380

 

Lee, K., Qian, D. Z., Rey, S., Wei, H., Liu, J. O., & Semenza, G. L. (2009a). Anthracycline chemotherapy inhibits HIF-1α transcriptional activity and tumor-induced mobilization of circulating angiogenic cells. Proceedings of the National Academy of Sciences of the United States of America, 106(7), 2353–2358. https://doi.org/10.1073/pnas.0812801106

 

Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009b). Acriflavine inhibits HIF-1α dimerization, tumor growth, and vascularization. Proceedings of the National Academy of Sciences of the United States of America, 106(42), 17910–17915. https://doi.org/10.1073/pnas.0909353106

 

Lee, K. M., Giltnane, J. M., Balko, J. M., Schwarz, L. J., Guerrero-Zotano, A. L., Hutchinson, K. E., Nixon, M. J., Estrada, M. V., Sanchez, V., Sanders, M. E., Lee, T., Gomez, H., Lluch, A., Perez-Fidalgo, J. A., Wolf, M. M., Andrejeva, G., Rathmell, J. C., Fesik, S. W., & Arteaga, C. L. (2017). MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation. Cell Metabolism, 26(4), 633–647.e7. https://doi.org/10.1016/j.cmet.2017.09.009

 

Lee, W. S., Yang, H., Chon, H. J., & Kim, C. (2020). Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Experimental & Molecular Medicine, 52(9), 1475–1485. https://doi.org/10.1038/s12276-020-00500-y

 

Lequeux, A., Noman, M. Z., Xiao, M., Van Moer, K., Hasmim, M., Benoit, A., Bosseler, M., Viry, E., Arakelian, T., Berchem, G., Chouaib, S., & Janji, B. (2021). Targeting HIF-1α transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy. Oncogene, 40(28), 4725–4735. https://doi.org/10.1038/s41388-021-01846-x

 

Li, C. Y., Shan, S., Huang, Q., Braun, R. D., Lanzen, J., Hu, K., Lin, P., & Dewhirst, M. W. (2000). Initial stages of tumor cell-induced angiogenesis: Evaluation via skin window chambers in rodent models. Journal of the National Cancer Institute, 92(2), 143–147. https://doi.org/10.1093/jnci/92.2.143

 

Li, Y., Zhu, R., He, X., Song, Y., Fan, T., Ma, J., Xiang, G., & Ma, X. (2024). Discovery of potent HIF-1α degraders by proteolysis targeting chimera (PROTAC). Bioorganic Chemistry, 153, 107943. https://doi.org/10.1016/j.bioorg.2024.107943

 

Lin, S., Chai, Y., Zheng, X., & Xu, X. (2023). The role of HIF in angiogenesis,  lymphangiogenesis, and tumor microenvironment in urological cancers. Molecular Biology Reports, 51(1). https://doi.org/10.1007/s11033-023-08931-2

 

Liu, J., Jiang, Y., Chen, L., Qian, Z., & Zhang, Y. (2024). Associations between HIFs and tumor immune checkpoints: Mechanism and therapy. Discover Oncology, 15(1). https://doi.org/10.1007/s12672-023-00836-7

 

Liu, S., Liu, X., Zhang, C., Shan, W., & Qiu, X. (2021). T-cell exhaustion status under high and low levels of HIF-1α expression in glioma. Frontiers in Pharmacology, 12. https://doi.org/10.3389/fphar.2021.711772

 

Liu, W., Dou, C., Zhang, C., Chen, P., Zhang, S., Wang, R., Han, Q., Zhao, H., & Li, D. (2024). PX-478 induces apoptosis in acute myeloid leukemia under hypoxia by inhibiting the PI3K/AKT/mTOR pathway through downregulation of GBE1. Biochemical Pharmacology, 230, 116620. https://doi.org/10.1016/j.bcp.2024.116620

 

Liu, Y., Cox, S. R., Morita, T., & Kourembanas, S. (1995). Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells: Identification of a 5› enhancer. Circulation Research, 77(3), 638–643. https://doi.org/10.1161/01.res.77.3.638

 

Lu, Y., Wang, B., Shi, Q., Wang, X., Wang, D., & Zhu, L. (2016). Brusatol inhibits HIF-1 signaling pathway and suppresses cells. Scientific Reports, 6(1). https://doi.org/10.1038/srep39123

 

Luo, Z., Tian, M., Yang, G., Tan, Q., Chen, Y., Li, G., Zhang, Q., Li, Y., Wan, P., & Wu, J. (2022). Hypoxia signaling in human health and diseases: Implications and prospects for therapeutics. Signal Transduction and Targeted Therapy, 7(1). https://doi.org/10.1038/s41392-022-01080-1

 

Ma, S., Zhao, Y., Lee, W. C., Ong, L.-T., Lee, P. L., Jiang, Z., Oguz, G., Niu, Z., Liu, M., Goh, J. Y., Wang, W., Bustos, M. A., Ehmsen, S., Ramasamy, A., Hoon, D. S. B., Ditzel, H. J., Tan, E. Y., Chen, Q., & Yu, Q. (2022). Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple-negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-31764-9

 

Mahon, P. C., Hirota, K., & Semenza, G. L. (2001). FIH-1: A novel protein that interacts with HIF-1α and VHL to mediate repression of HIF-1α transcriptional activity. Genes & Development, 15(20), 2675–2686. https://doi.org/10.1101/gad.924501

 

Makino, Y., Kanopka, A., Wilson, W. J., Tanaka, H., & Poellinger, L. (2002). Inhibitory PAS domain protein (IPAS) is a hypoxia-inducible splicing variant of the HIF-3α locus. Journal of Biological Chemistry, 277(36), 32405–32408. https://doi.org/10.1074/jbc.C200328200

 

Mal, A., Xie, B., Gray, Z., Small, C., Ramanand, S. G., Gao, Y., Toffessi Tcheuyap, V., Debnath, S., Christie, A., Miyata, J., Jackson, B., Zhong, H., Gao, B., Lohrey, J., Maalouf, N. M., Reddy, S. M., Minna, J. D., Pedrosa, I., Sun, X., … Brugarolas, J. (2025). HIF-2α-dependent regulation of PTHrP and paraneoplastic hypercalcemia in aggressive clear-cell renal cell carcinoma. Cancer Discovery, 15(12), 2485–2504. https://doi.org/10.1158/2159-8290.Cd-25-0638

 

Mangraviti, A., Raghavan, T., Volpin, F., Skuli, N., Gullotti, D., Zhou, J., Asnaghi, L., Sankey, E., Liu, A., Wang, Y., Lee, D.-H., Gorelick, N., Serra, R., Peters, M., Schriefer, D., Delaspre, F., Rodriguez, F. J., Eberhart, C. G., Brem, H., …Tyler, B. (2017). HIF-1α-targeting acriflavine provides long term survival and radiological tumor response in brain cancer therapy. Scientific Reports, 7(1). https://doi.org/10.1038/s41598-017-14990-w

 

Michiels, C., Tellier, C., & Feron, O. (2016). Cycling hypoxia: A key feature of the tumor microenvironment. *Biochimica et Biophysica Acta - Reviews on Cancer, 1866*(1), 76–86. https://doi.org/10.1016/j.bbcan.2016.06.004

 

Mimeault, M., & Batra, S. K. (2013). Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells. Journal of Cellular and Molecular Medicine, 17(1), 30–54. https://doi.org/10.1111/jcmm.12004

 

Mira, E., Carmona-Rodriguez, L., Perez-Villamil, B., Casas, J., Fernandez-Acenero, M. J., Martinez-Rey, D., Martin-Gonzalez, P., Heras-Murillo, I., Paz-Cabezas, M., Tardaguila, M., Oury, T. D., Martin-Puig, S., Lacalle, R. A., Fabrias, G., Diaz-Rubio, E., & Manes, S. (2018). SOD3 improves the tumor response to chemotherapy by stabilizing endothelial HIF-2α. Nature Communications, 9(1). https://doi.org/10.1038/s41467-018-03079-1

 

Miranda, E., Nordgren, I. K., Male, A. L., Lawrence, C. E., Hoakwie, F., Cuda, F., Court, W., Fox, K. R., Townsend, P. A., Packham, G. K., Eccles, S. A., & Tavassoli, A. (2013). A cyclic peptide inhibitor of HIF-1α heterodimerization that inhibits hypoxia signaling in cancer cells. Journal of the American Chemical Society, 135(28), 10418–10425. https://doi.org/10.1021/ja402993u

 

Miska, J., Lee-Chang, C., Rashidi, A., Muroski, M. E., Chang, A. L., Lopez-Rosas, A., Zhang, P., Panek, W. K., Cordero, A., Han, Y., Ahmed, A. U., Chandel, N. S., & Lesniak, M. S. (2022). HIF-1α is a metabolic switch between glycolytic-driven migration and oxidative phosphorylation-driven immunosuppression of Tregs in glioblastoma. Cell Reports, 39(10), 110934. https://doi.org/10.1016/j.celrep.2022.110934

 

Missiaen, R., Lesner, N. P., & Simon, M. C. (2023). HIF: A master regulator of nutrient availability and metabolic cross-talk in the tumor microenvironment. EMBO Journal, 42(6). https://doi.org/10.15252/embj.2022112067

 

Moon, E. J., Mello, S. S., Li, C. G., Chi, J. T., Thakkar, K., Kirkland, J. G., Lagory, E. L., Lee, I. J., Diep, A. N., Miao, Y., Rafat, M., Vilalta, M., Castellini, L., Krieg, A. J., Graves, E. E., Attardi, L. D., & Giaccia, A. J. (2021). The HIF target MAFF promotes tumor invasion and metastasis through IL11 and STAT3 signaling. Nature Communications, 12(1). https://doi.org/10.1038/s41467-021-24631-6

 

Mpekris, F., Voutouri, C., Baish, J. W., Duda, D. G., Munn, L. L., Stylianopoulos, T., & Jain, R. K. (2020). Combining microenvironment normalization strategies to improve cancer immunotherapy. Proceedings of the National Academy of Sciences of the United States of America, 117(7), 3728–3737. https://doi.org/10.1073/pnas.1919764117

 

Nakazawa, T., Morimoto, T., Maeoka, R., Yamada, K., Matsuda, R., Nakamura, M., Nishimura, F., Yamada, S., Park, Y. S., Tsujimura, T., & Nakagawa, I. (2024). Characterization of HIF-1α knockout primary human natural killer cells including populations in allogeneic glioblastoma. International Journal of Molecular Sciences, 25(11), 5896.  https://doi.org/10.3390/ijms25115896

 

Naldini, A., Morena, E., Pucci, A., Pellegrini, M., Baldari, C. T., Pelicci, P. G., Presta, M., Ribatti, D., & Carraro, F. (2010). The adaptor protein p66Shc is a positive regulator in the angiogenic response induced by hypoxic T cells. Journal of Leukocyte Biology, 87(3), 365–369. https://doi.org/10.1189/jlb.0709460

 

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., Timmerman, J. M., Stiff, P. J., Friedberg, J. W., Flinn, I. W., Goy, A., Hill, B. T., Smith, M. R., Deol, A., Farooq, U., … Go, W. Y. (2017). Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England Journal of Medicine, 377(26), 2531–2544. https://doi.org/10.1056/NEJMoa1707447

 

Ni, J., Wang, X., Stojanovic, A., Zhang, Q., Wincher, M., Buhler, L., Arnold, A., Correia, M. P., Winkler, M., Koch, P. S., Sexl, V., Hofer, T., & Cerwenka, A. (2020). Single-cell RNA sequencing of tumor-infiltrating NK cells reveals that inhibition of transcription factor HIF-1α unleashes NK cell activity. Immunity, 52(6), 1075–1087.e8. https://doi.org/10.1016/j.immuni.2020.05.001

 

Nicolini, A., & Ferrari, P. (2024). Involvement of tumor immune microenvironment metabolic reprogramming in colorectal cancer progression, immune escape, and response to immunotherapy. Frontiers in Immunology, 15. https://doi.org/10.3389/fimmu.2024.1353787

 

Ning, F., Takeda, K., Schedel, M., Domenico, J., Joetham, A., & Gelfand, E. W. (2019). Hypoxia enhances CD8+ T(C)2 cell-dependent airway hyperresponsiveness and inflammation through HIF-1α. Journal of Allergy and Clinical Immunology, 143(6), 2026–2037.e7. https://doi.org/10.1016/j.jaci.2018.11.049

 

Niu, Y., Chen, Y., Sun, P., Wang, Y., Luo, J., Ding, Y., & Xie, W. (2021). Intragastric and atomized administration of canagliflozin inhibit inflammatory cytokine storm in lipopolysaccharide-treated sepsis in mice: A potential COVID-19 treatment. International Immunopharmacology, 96, 107773. https://doi.org/10.1016/j.intimp.2021.107773

 

Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014). PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. Journal of Experimental Medicine, 211(5), 781–790. https://doi.org/10.1084/jem.20131916

 

Obeagu, E. I. (2025). Hypoxia-driven angiogenesis in breast cancer mechanisms and therapeutic targets: A narrative review. Annals of Medicine & Surgery, 87(7), 4246–4254. https://doi.org/10.1097/ms9.0000000000003411

 

Oh, E. T., Kim, C. W., Kim, H. G., Lee, J. S., & Park, H. J. (2017). Brusatol-mediated inhibition of c-Myc increases HIF-1α degradation and causes cell death in colorectal cancer under hypoxia. Theranostics, 7(14), 3415–3431. https://doi.org/10.7150/thno.20861

 

Palazon, A., Tyrakis, P. A., Macias, D., Velica, P., Rundqvist, H., Fitzpatrick, S., Vojnovic, N., Phan, A. T., Loman, N., Hedenfalk, I., Hatschek, T., Lovrot, J., Foukakis, T., Goldrath, A. W., Bergh, J., & Johnson, R. S. (2017). An HIF-1α/VEGF-A axis in cytotoxic T cells regulates tumor progression. Cancer Cell, 32(5), 669–683.e5. https://doi.org/10.1016/j.ccell.2017.10.003

 

Park, J. S., Kim, I. K., Han, S., Park, I., Kim, C., Bae, J., Oh, S. J., Lee, S., Kim, J. H., Woo, D. C., He, Y., Augustin, H. G., Kim, I., Lee, D., & Koh, G. Y. (2016). Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment. Cancer Cell, 30(6), 953–967. https://doi.org/10.1016/j.ccell.2016.10.018

 

Partch, C. L., & Gardner, K. H. (2011). Coactivators necessary for transcriptional output of the hypoxia inducible factor, HIF, are directly recruited by ARNT PAS-B. Proceedings of the National Academy of Sciences of the United States of America, 108(19), 7739–7744. https://doi.org/10.1073/pnas.1101357108

 

Peng, H., Yao, F., Zhao, J., Zhang, W., Chen, L., Wang, X., Yang, P., Tang, J., & Chi, Y. (2023). Unraveling mitochondria-targeting reactive oxygen species modulation and their implementations in cancer therapy by nanomaterials. Exploration, 3(2). https://doi.org/10.1002/exp.20220115

 

Powles, T., Albiges, L., & Rini, B. (2024). Belzutifan versus everolimus for advanced renal-cell carcinoma: Reply. New England Journal of Medicine, 391(21), 2062–2063. https://doi.org/10.1056/NEJMc2411843

 

Qannita, R. A., Alalami, A. I., Harb, A. A., Aleidi, S. M., Taneera, J., Abu-Gharbieh, E., El-Huneidi, W., Saleh, M. A., Alzoubi, K. H., Semreen, M. H., Hudaib, M., & Bustanji, Y. (2024). Targeting HIF-1α in cancer: Emerging therapeutic strategies and pathway regulation. Pharmaceuticals, 17(2), 195. https://doi.org/10.3390/ph17020195

 

Riley, J. L. (2009). PD-1 signaling in primary T cells. Immunological Reviews, 229(1), 114–125. https://doi.org/10.1111/j.1600-065X.2009.00767.x

 

Rohwer, N., Jumpertz, S., Erdem, M., Egners, A., Warzecha, K. T., Fragoulis, A., Kuhl, A. A., Kramann, R., Neuss, S., Rudolph, I., Endermann, T., Zasada, C., Apostolova, I., Gerling, M., Kempa, S., Hughes, R., Lewis, C. E., Brenner, W., Malinowski, M. B., … Cramer, T. (2019). Noncanonical HIF-1α stabilization contributes to intestinal tumorigenesis. Oncogene, 38(28), 5670–5685. https://doi.org/10.1038/s41388-019-0816-4

 

Ryan, H. E., Poloni, M., McNulty, W., Elson, D., Gassmann, M., Arbeit, J. M., & Johnson, R. S. (2000). HIF-1α is a positive factor in solid tumor growth. Cancer Research, 60(15), 4010–4015.

 

Salceda, S., & Caro, J. (1997). HIF-1α protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions: Its stabilization by hypoxia depends on redox-induced changes. Journal of Biological Chemistry, 272(36), 22642–22647. https://doi.org/10.1074/jbc.272.36.22642

 

Scheuermann, T. H., Li, Q., Ma, H. W., Key, J., Zhang, L., Chen, R., Garcia, J. A., Naidoo, J., Longgood, J., Frantz, D. E., Tambar, U. K., Gardner, K. H., & Bruick, R. K. (2013). Allosteric inhibition of HIF-2α with small molecules. Nature Chemical Biology, 9(4), 271–276. https://doi.org/10.1038/nchembio.1185

 

Semenza, G. L. (2002). HIF-1α and tumor progression: Pathophysiology and therapeutics. Trends in Molecular Medicine, 8(4), S62–S67. https://doi.org/10.1016/s1471-4914(02)02317-1

 

Semenza, G. L. (2012). HIFs in physiology and medicine. Cell, 148(3), 399–408. https://doi.org/10.1016/j.cell.2012.01.021

 

Semenza, G. L. (2013). HIF-1α mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. Journal of Clinical Investigation, 123(9), 3664–3671. https://doi.org/10.1172/jci67230

 

Semenza, G. L. (2021). Intratumoral hypoxia and mechanisms of immune evasion mediated by hypoxia-inducible factors. Physiology, 36(2), 73–83. https://doi.org/10.1152/physiol.00034.2020

 

Semenza, G. L., Agani, F., Booth, G., Forsythe, J., Iyer, N., Jiang, B. H., Leung, S., Roe, R., Wiener, C., & Yu, A. (1997). Structural and functional analysis of HIF-1. Kidney International, 51(2), 553–555. https://doi.org/10.1038/ki.1997.77

 

Semenza, G. L., Nejfelt, M. K., Chi, S. M., & Antonarakis, S. E. (1991). Hypoxia-inducible nuclear factors bind to an enhancer element located 3› to the human erythropoietin gene. Proceedings of the National Academy of Sciences of the United States of America, 88(13), 5680–5684. https://doi.org/10.1073/pnas.88.13.5680

 

Shen, H., Ojo, O. A., Ding, H., Mullen, L. J., Xing, C., Hossain, M. I., Yassin, A., Shi, V. Y., Lewis, Z., Podgorska, E., Andrabi, S. A., Antoniewicz, M. R., Bonner, J. A., & Shi, L. Z. (2024). HIF1α-regulated glycolysis promotes activation-induced cell death and IFN-γ induction in hypoxic T cells. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-53593-8

 

Shin, S., Choi, Y., Jang, W., Ulziituya, B., Ha, G., Kang, R., Park, S., Kim, M., Zhang, Y. S., Kim, H. J., & Lee, J. (2025). A vascularized tumors-on-a-chip model for studying tumor-angiogenesis interplay, heterogeneity and drug responses. Materials Today Bio, 32, 101741. https://doi.org/10.1016/j.mtbio.2025.101741

 

Song, S., Zhang, Y., Duan, X., Liu, C., Du, Y., Wang, X., Luo, Y., & Cui, Y. (2023). HIF-1α/IL-8 axis in hypoxic macrophages promotes esophageal cancer progression by enhancing PD-L1 expression. Cancer Gene Therapy, 30(2), 358–367. https://doi.org/10.1038/s41417-022-00551-5

 

Sullivan, R., Pare, G. C., Frederiksen, L. J., Semenza, G. L., & Graham, C. H. (2008). Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires HIF-1α activity. Molecular Cancer Therapeutics, 7(7), 1961–1973. https://doi.org/10.1158/1535-7163.Mct-08-0198

 

Sun, R. C., & Denko, N. C. (2014). Hypoxic regulation of glutamine metabolism through HIF-1α and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metabolism, 19(2), 285–292. https://doi.org/10.1016/j.cmet.2013.11.022

 

Sun, X., Wei, L., Chen, Q., & Terek, R. M. (2010). CXCR4/SDF1 mediate hypoxia induced chondrosarcoma cell invasion through ERK signaling and increased MMP1 expression. Molecular Cancer, 9(1). https://doi.org/10.1186/1476-4598-9-17

 

Susen, R. M., Bauer, R., Olesch, C., Fuhrmann, D. C., Fink, A. F., Dehne, N., Jain, A., Ebersberger, I., Schmid, T., & Brune, B. (2019). Macrophage HIF-2α regulates tumor-suppressive Spint1 in the tumor microenvironment. Molecular Carcinogenesis, 58(11), 2127–2138. https://doi.org/10.1002/mc.23103

 

Takeda, N., O’Dea, E. L., Doedens, A., Kim, J. W., Weidemann, A., Stockmann, C., Asagiri, M., Simon, M. C., Hoffmann, A., & Johnson, R. S. (2010). Differential activation and antagonistic function of HIF-α isoforms in macrophages are essential for NO homeostasis. Genes & Development, 24(5), 491–501. https://doi.org/10.1101/gad.1881410

 

Tanaka, T., Yamaguchi, J., Shoji, K., & Nangaku, M. (2012). Anthracycline inhibits recruitment of hypoxia-inducible transcription factors and suppresses tumor cell migration and cardiac angiogenic response in the host. Journal of Biological Chemistry, 287(42), 34866–34882. https://doi.org/10.1074/jbc.M112.374587

 

Tang, N., Wang, L., Esko, J., Giordano, F. J., Huang, Y., Gerber, H. P., Ferrara, N., & Johnson, R. S. (2004). Loss of HIF-1α in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. Cancer Cell, 6(5), 485–495. https://doi.org/10.1016/j.ccr.2004.09.026

 

Taylor, C. T., & Scholz, C. C. (2022). The effect of HIF on metabolism and immunity. Nature Reviews Nephrology, 18(9), 573–587. https://doi.org/10.1038/s41581-022-00587-8

 

Tojo, Y., Sekine, H., Hirano, I., Pan, X., Souma, T., Tsujita, T., Kawaguchi, S., Takeda, N., Takeda, K., Fong, G. H., Dan, T., Ichinose, M., Miyata, T., Yamamoto, M., & Suzuki, N. (2015). Hypoxia signaling cascade for erythropoietin production in hepatocytes. Molecular and Cellular Biology, 35(15), 2658–2672. https://doi.org/10.1128/mcb.00161-15

 

Valdes, A., Pizarro, G., Gonzalez-Montero, J., Rojas, C., & Burotto, M. (2024). Targeting HIF-2α: The role of belzutifan in clear cell renal carcinoma management. Expert Review of Clinical Pharmacology, 18(1-2), 17–27. https://doi.org/10.1080/17512433.2024.2436433

 

Vaupel, P. (2004). Tumor microenvironmental physiology and its implications for radiation oncology. Seminars in Radiation Oncology, 14(3), 198–206. https://doi.org/10.1016/j.semradonc.2004.04.008

 

Vignali, P. D. A., DePeaux, K., Watson, M. J., Ye, C., Ford, B. R., Lontos, K., McGaa, N. K., Scharping, N. E., Menk, A. V., Robson, S. C., Poholek, A. C., Rivadeneira, D. B., & Delgoffe, G. M. (2023). Hypoxia drives CD39-dependent suppressor function in exhausted T cells to limit antitumor immunity. Nature Immunology, 24(2), 267–279. https://doi.org/10.1038/s41590-022-01379-9

 

Villa-Roel, N., Ryu, K., Gu, L., Fernandez Esmerats, J., Kang, D. W., Kumar, S., & Jo, H. (2022). HIF-1α inhibitor PX-478 reduces atherosclerosis in mice. Atherosclerosis, 344, 20–30. https://doi.org/10.1016/j.atherosclerosis.2022.01.002

 

Wallace, E. M., Rizzi, J. P., Han, G., Wehn, P. M., Cao, Z., Du, X., Cheng, T., Czerwinski, R. M., Dixon, D. D., Goggin, B. S., Grina, J. A., Halfmann, M. M., Maddie, M. A., Olive, S. R., Schlachter, S. T., Tan, H., Wang, B., Wang, K., Xie, S., … Josey, J. A. (2016). A small-molecule antagonist of HIF-2α is efficacious in preclinical models of renal cell carcinoma. Cancer Research, 76(18), 5491–5500. https://doi.org/10.1158/0008-5472.Can-16-0473

 

Wang, G. L., & Semenza, G. L. (1993). General involvement of HIF-1α in transcriptional response to hypoxia. Proceedings of the National Academy of Sciences of the United States of America, 90(9), 4304–4308. https://doi.org/10.1073/pnas.90.9.4304

 

Wang, Q., Yuan, F., Zuo, X., & Li, M. (2025). Breakthroughs and challenges of organoid models for assessing cancer immunotherapy: A cutting-edge tool for advancing personalised treatments. Cell Death Discovery, 11(1). https://doi.org/10.1038/s41420-025-02505-w

 

Weber, E. W., Parker, K. R., Sotillo, E., Lynn, R. C., Anbunathan, H., Lattin, J., Good, Z., Belk, J. A., Daniel, B., Klysz, D., Malipatlolla, M., Xu, P., Bashti, M., Heitzeneder, S., Labanieh, L., Vandris, P., Majzner, R. G., Qi, Y., Sandor, K., … Mackall, C. L. (2021). Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science, 372(6537). https://doi.org/10.1126/science.aba1786

 

Wei, P., Kou, W., Riaz, F., Zhang, K., Fu, J., & Pan, F. (2023). Combination therapy of HIF-α inhibitors and Treg depletion strengthen the anti-tumor immunity in mice. European Journal of Immunology, 53(12). https://doi.org/10.1002/eji.202250182

 

Wenes, M., Shang, M., Di Matteo, M., Goveia, J., Martin-Perez, R., Serneels, J., Prenen, H., Ghesquiere, B., Carmeliet, P., & Mazzone, M. (2016). Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis. Cell Metabolism, 24(5), 701–715. https://doi.org/10.1016/j.cmet.2016.09.008

 

Werter, I. M., Huijts, C. M., Lougheed, S. M., Hamberg, P., Polee, M. B., Tascilar, M., Los, M., Haanen, J., Helgason, H. H., Verheul, H. M., de Gruijl, T. D., & van der Vliet, H. J. (2019). Metronomic cyclophosphamide attenuates mTOR-mediated expansion of regulatory T cells, but does not impact clinical outcome in patients with metastatic renal cell cancer treated with everolimus. Cancer Immunology, Immunotherapy, 68(5), 787–798. https://doi.org/10.1007/s00262-019-02313-z

 

Wicks, E. E., & Semenza, G. L. (2022). Hypoxia-inducible factors: Cancer progression and clinical translation. Journal of Clinical Investigation, 132(11). https://doi.org/10.1172/jci159839

 

Wood, S. M., Gleadle, J. M., Pugh, C. W., Hankinson, O., & Ratcliffe, P. J. (1996). The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression: Studies in ARNT-deficient cells. Journal of Biological Chemistry, 271(25), 15117–15123. https://doi.org/10.1074/jbc.271.25.15117

 

Wu, D., & Rastinejad, F. (2017). Structural characterization of mammalian bHLH-PAS transcription factors. Current Opinion in Structural Biology, 43, 1–9. https://doi.org/10.1016/j.sbi.2016.09.011

 

Wu, H., Zhao, X., Hochrein, S. M., Eckstein, M., Gubert, G. F., Knopper, K., Mansilla, A. M., Oner, A., Doucet-Ladeveze, R., Schmitz, W., Ghesquiere, B., Theurich, S., Dudek, J., Gasteiger, G., Zernecke, A., Kobold, S., Kastenmuller, W., & Vaeth, M. (2023). Mitochondrial dysfunction promotes the transition of precursor to terminally exhausted T cells through HIF-1α-mediated glycolytic reprogramming. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-42634-3

 

Wu, Z., Man, S., Sun, R., Li, Z., Wu, Y., & Zuo, D. (2020). Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer. International Immunopharmacology, 85, 106613. https://doi.org/10.1016/j.intimp.2020.106613

 

Xie, D., Wang, J., Hu, G., Chen, C., Yang, H., Ritter, J. K., Qu, Y., & Li, N. (2021). Kidney-targeted delivery of prolyl hydroxylase domain protein 2 small interfering RNA with nanoparticles alleviated renal ischemia/reperfusion injury. Journal of Pharmacology and Experimental Therapeutics, 378(3), 235–243. https://doi.org/10.1124/jpet.121.000667

 

Xu, R., Wang, K., Rizzi, J. P., Huang, H., Grina, J. A., Schlachter, S. T., Wang, B., Wehn, P. M., Yang, H., Dixon, D. D., Czerwinski, R. M., Du, X., Ged, E. L., Han, G., Tan, H., Wong, T., Xie, S., Josey, J. A., & Wallace, E. M. (2019). 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-zethylsulfonylindan-4-yl] oxy-5-fluorobenzonitrile (PT2977), a HIF-2α inhibitor for the  treatment of clear cell renal cell carcinoma. Journal of Medicinal Chemistry, 62(15), 6876–6893. https://doi.org/10.1021/acs.jmedchem.9b00719

 

Xue, X., Qu, H., & Li, Y. (2022). Stimuli-responsive crosslinked nanomedicine for cancer treatment. Exploration, 2(6). https://doi.org/10.1002/exp.20210134

 

Xun, Z., Zhou, H., Shen, M., Liu, Y., Sun, C., Du, Y., Jiang, Z., Yang, L., Zhang, Q., Lin, C., Hu, Q., Ye, Y., & Han, L. (2024). Identification of hypoxia-ALCAM (high) macrophage exhausted T cell axis in tumor microenvironment remodeling for immunotherapy resistance. Advanced Science, 11(33). https://doi.org/10.1002/advs.202309885

 

Yan, Y., Liu, F., Han, L., Zhao, L., Chen, J., Olopade, O. I., He, M., & Wei, M. (2018). HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways. Journal of Experimental & Clinical Cancer Research, 37(1). https://doi.org/10.1186/s13046-018-0925-x

 

Yang, M. H., Wu, M. Z., Chiou, S. H., Chen, P. M., Chang, S. Y., Liu, C. J., Teng, S. C., & Wu, K. J. (2008). Direct regulation of TWIST by HIF-1α promotes metastasis. Nature Cell Biology, 10(3), 295–305. https://doi.org/10.1038/ncb1691

 

Yuan, X., Ruan, W., Bobrow, B., Carmeliet, P., & Eltzschig, H. K. (2023). Targeting HIFs: Therapeutic opportunities and challenges. Nature Reviews Drug Discovery, 23(3), 175–200. https://doi.org/10.1038/s41573-023-00848-6

 

Zandberg, D. P., Menk, A. V., Velez, M., Normolle, D., DePeaux, K., Liu, A., Ferris, R. L., & Delgoffe, G. M. (2021). Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck. Journal for ImmunoTherapy of Cancer, 9(5), e002088. https://doi.org/10.1136/jitc-2020-002088

 

Zhang, H., Brown, R. L., Wei, Y., Zhao, P., Liu, S., Liu, X., Deng, Y., Hu, X., Zhang, J., Gao, X. D., Kang, Y., Mercurio, A. M., Goel, H. L., & Cheng, C. (2019). CD44 splice isoform switching determines breast cancer stem cell state. Genes & Development, 33(3-4), 166–179. https://doi.org/10.1101/gad.319889.118

 

Zhang, H., Qian, D. Z., Tan, Y. S., Lee, K., Gao, P., Ren, Y. R., Rey, S., Hammers, H., Chang, D., Pili, R., Dang, C. V., Liu, J. O., & Semenza, G. L. (2008). Digoxin and other cardiac glycosides inhibit HIF-1α synthesis and block tumor growth. Proceedings of the National Academy of Sciences of the United States of America, 105(50), 19579–19586. https://doi.org/10.1073/pnas.0809763105

 

Zhang, L., Cagle, C., Nguyen, D. H., Gomes, G. S., Gromova, B., Csizmadia, E., Karimitar, A., Lee, G. R., Chen, G., Kokkotou, E., Grossberg, L., Jiang, S., Cheifetz, A. S., Kota, S. K., & Longhi, M. S. (2025). Antisense to human CD39 dysregulates immune metabolism in inflammatory bowel disease. Cellular & Molecular Immunology, 22(7), 730–742. https://doi.org/10.1038/s41423-025-01295-6

 

Zhang, T. Q., Lv, Q. Y., & Jin, W. L. (2024). The cellular-centered view of hypoxia tumor microenvironment: Molecular mechanisms and therapeutic interventions. *Biochimica et Biophysica Acta - Reviews on Cancer, 1879*(5), 189137. https://doi.org/10.1016/j.bbcan.2024.189137

 

Zhang, Y., Kurupati, R., Liu, L., Zhou, X. Y., Zhang, G., Hudaihed, A., Filisio, F., Giles-Davis, W., Xu, X., Karakousis, G. C., Schuchter, L. M., Xu, W., Amaravadi, R., Xiao, M., Sadek, N., Krepler, C., Herlyn, M., Freeman, G. J., Rabinowitz, J. D., & Ertl, H. C. J. (2017). Enhancing CD8+ T cell fatty acid catabolism within a metabolically challenging tumor microenvironment increases the efficacy of melanoma immunotherapy. Cancer Cell, 32(3), 377–391.e9. https://doi.org/10.1016/j.ccell.2017.08.004

 

Zheng, S., Ni, J., Li, Y., Lu, M., Yao, Y., Guo, H., Jiao, M., Jin, T., Zhang, H., Yuan, A., Wang, Z., Yang, Y., Chen, Z., Wu, H., & Hu, W. (2021). 2-Methoxyestradiol synergizes with erlotinib to suppress hepatocellular carcinoma by disrupting the PLAGL2-EGFR-HIF-1/2α signaling loop. Pharmacological Research, 169, 105685. https://doi.org/10.1016/j.phrs.2021.105685

 

Zheng, X., Qian, Y., Fu, B., Jiao, D., Jiang, Y., Chen, P., Shen, Y., Zhang, H., Sun, R., Tian, Z., & Wei, H. (2019). Mitochondrial fragmentation limits NK cell-based tumor immunosurveillance. Nature Immunology, 20(12), 1656–1667. https://doi.org/10.1038/s41590-019-0511-1

 

Zhou, M., Xu, L., Hu, J., Chen, W., Hong, J., Wang, M., & Guo, Z. (2025). Metabolic reprogramming through PIM3 inhibition reverses hypoxia-induced CAR-T cell dysfunction in solid tumors. Journal of Translational Medicine, 23(1). https://doi.org/10.1186/s12967-025-07278-5

 

Zhou, X., Guo, X., Chen, M., Xie, C., & Jiang, J. (2018). HIF-3α promotes metastatic phenotypes in pancreatic cancer by transcriptional regulation of the RhoC-ROCK1 signaling pathway. Molecular Cancer Research, 16(1), 124–134. https://doi.org/10.1158/1541-7786.Mcr-17-0256